A phase III trial testing Astellas Pharma Inc.’s acute myeloid leukemia (AML) candidate, gilteritinib, as a maintenance therapy after hematopoietic stem cell transplant (HCT) has dosed its first patient. It’s the fourth late-stage trial testing the FLT3/Axl kinase inhibitor in an active landscape of increasingly tailored AML therapies. If successful, the study could help the company establish a basis for a potentially broad label for the orphan-designated medicine.